Cargando…

Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects

Objective: Omecamtiv mecarbil is a novel small molecule that directly activates cardiac myosin and increases cardiac contractility without increasing cardiac myocyte intracellular calcium. This study evaluated the relative bioavailability, food effect, and safety of several modified-release (MR) for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palaparthy, Rameshraja, Banfield, Christopher, Alvarez, Paco, Yan, Lucy, Smith, Brian, Johnson, Jessica, Monsalvo, Maria Laura, Malik, Fady
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776255/ https://www.ncbi.nlm.nih.gov/pubmed/26709596 http://dx.doi.org/10.5414/CP202458

Ejemplares similares

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
por: Trivedi, Ashit, et al.
Publicado: (2021)

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects
por: Trivedi, Ashit, et al.
Publicado: (2021)

Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
por: Planelles-Herrero, Vicente J., et al.
Publicado: (2017)

Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil
por: Hashem, Shaima, et al.
Publicado: (2017)

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury
por: Stroethoff, Martin, et al.
Publicado: (2019)

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
por: Kaplinsky, Edgardo, et al.
Publicado: (2018)

Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans
por: Fülöp, Gábor Á., et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
por: Dashwood, Alexander, et al.
Publicado: (2021)

Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil
por: Governali, Serena, et al.
Publicado: (2020)

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
por: Metra, Marco, et al.
Publicado: (2022)

Effects of omecamtiv mecarbil on calcium‐transients and contractility in a translational canine myocyte model
por: Gao, BaoXi, et al.
Publicado: (2020)

Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management
por: Patel, Pooja H, et al.
Publicado: (2021)

cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation
por: Mamidi, Ranganath, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on the contractile properties of skinned porcine left atrial and ventricular muscles
por: Nakanishi, Tomohiro, et al.
Publicado: (2022)

Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis
por: Alqatati, Fadel, et al.
Publicado: (2022)

Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil
por: El Oumeiri, Bachar, et al.
Publicado: (2023)

Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study
por: Felker, G. Michael, et al.
Publicado: (2020)

Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
por: El-Oumeiri, Bachar, et al.
Publicado: (2018)

Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
por: Woody, Michael S., et al.
Publicado: (2018)

Omecamtiv mecarbil lowers the contractile deficit in a mouse model of nebulin-based nemaline myopathy
por: Lindqvist, Johan, et al.
Publicado: (2019)

Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca(2+) levels
por: Ráduly, Arnold Péter, et al.
Publicado: (2023)

The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation
por: El Oumeiri, Bachar, et al.
Publicado: (2021)

Comprehensive in vitro pro‐arrhythmic assays demonstrate that omecamtiv mecarbil has low pro‐arrhythmic risk
por: Qu, Yusheng, et al.
Publicado: (2021)

Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model
por: Wu, Shih-Ni, et al.
Publicado: (2022)

Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action
por: Parikh, Jaimit, et al.
Publicado: (2021)

Characterization of Stimulatory Action on Voltage-Gated Na(+) Currents Caused by Omecamtiv Mecarbil, Known to Be a Myosin Activator
por: Ting, Chih-Yu, et al.
Publicado: (2023)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model
por: Trivedi, Ashit, et al.
Publicado: (2021)

Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co‐treatment in pigs with acute ischemic heart failure
por: Rønning, Leif, et al.
Publicado: (2018)

Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil
por: Snoberger, Aaron, et al.
Publicado: (2021)

Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree(TM)) in Healthy Adult Subjects
por: Wang, Zhao, et al.
Publicado: (2021)

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
por: Scheidel, Bernhard, et al.
Publicado: (2017)

The Bioavailability and Pharmacokinetics of Silymarin SMEDDS Formulation Study in Healthy Thai Volunteers
por: Sornsuvit, Chuleegone, et al.
Publicado: (2018)

Pharmacokinetics of Morphine Sulfate Orodispersible Tablets and Bioequivalence with Immediate-Release Oral Morphine Sulfate Formulations in Healthy Adult Subjects Under Fasting Conditions: Single-Dose Comparative Bioavailability Studies
por: Atrux-Tallau, Nicolas, et al.
Publicado: (2022)

Pharmacokinetic and Bioavailability Studies of Embelin after Intravenous and Oral Administration to Rats
por: Li, Zhen, et al.
Publicado: (2019)

Study on Pharmacokinetic and Bioavailability of Tamarixetin after Intravenous and Oral Administration to Rats
por: Shen, Jiayuan, et al.
Publicado: (2019)

Bioavailability and pharmacokinetic comparison of tanshinones between two formulations of Salvia miltiorrhiza in healthy volunteers
por: Xing, Lu, et al.
Publicado: (2017)

Pharmacokinetic Profile and Oral Bioavailability of Diosgenin, Charantin, and Hydroxychalcone From a Polyherbal Formulation
por: Salunkhe, Ruchira, et al.
Publicado: (2021)

Comparative Bioavailability of Two Diosmin Formulations after Oral Administration to Healthy Volunteers
por: Russo, Rosario, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2blq5sfpuacg0gdnnhs2f8q22a